The short version of Incretin hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
ATP + NH3 + CO2 ⇌ ADP + H2N−C(=O)−O−PO2−3 An important example of an enzyme with this activity is carbamoyl phosphate synthetase, e.g. carbamoyl phosphate synthetase I carrying out the first step of the urea cycle in order to dispose of waste ammonia. One hemoglobin molecule can carry four molecules of carbon dioxide to the lungs as carbamate groups formed by reaction of CO2 with four terminal amine groups of the deoxy form. The resulting compound is called carbaminohaemoglobin.
For even higher stresses, materials exhibit plastic behavior, that is, they deform irreversibly and do not return to their original shape after stress is no longer applied. For rubber-like materials such as elastomers, the slope of the stress–strain curve increases with stress, meaning that rubbers progressively become more difficult to stretch, while for most metals, the gradient decreases at very high stresses, meaning that they progressively become easier to stretch. Elasticity is not exhibited only by solids; non-Newtonian fluids, such as viscoelastic fluids, will also exhibit elasticity in certain conditions quantified by the Deborah number. In response to a small, rapidly applied and removed strain, these fluids may deform and then return to their original shape. Under larger strains, or strains applied for longer periods of time, these fluids may start to flow like a viscous liquid. Because the elasticity of a material is described in terms of a stress–strain relation, it is essential that the terms stress and strain be defined without ambiguity. Typically, two types of relation are considered. The first type deals with materials that are elastic only for small strains. The second deals with materials that are not limited to small strains. Clearly, the second type of relation is more general in the sense that it must include the first type as a special case.
=== Industrial farms === Little research has been done on humane methods of killing insects for consumption. The most common killing methods used by entomophagy companies in the Netherlands are freezing and dry-freezing (i.e., freezing and reducing pressure in order to extract water from the insects). Protix Biosystems kills its black soldier flies by shredding, since its end product is a powder. Death takes less than a second. Tarique Arsiwalla at Protix said shredding makes sense because Western consumers are more likely to accept powdered insects than whole insects. The Jagran company has tried asphyxiation, cooling, freeze-drying, boiling, and shredding. Managing Director Walter Jansen believes that shredding is most humane. The Kreca company kills its animal-feed insects by putting them into a fridge or freeze-drying them. Insects destined for human consumption are first sterilized in hot water and then are refrigerated or freeze-dried. FAO's "Edible insects" report suggests: "Insect-killing methods that would reduce suffering include freezing or instantaneous techniques such as shredding."
A randomized trial is "Blind" if the participant is not told which arm of the trial he is on. A clinical trial is "Blind" if participants are unaware on whether they are in the experimental or control arm of the study; also called masked. (NLM) A procedure in which one or more parties to the trial are kept unaware of the treatment assignment(s). Single blinding usually refers to the subject(s) being unaware, and double blinding usually refers to the subject(s), investigator(s), monitor, and, in some cases, data analyst(s) being unaware of the treatment assignment(s). (ICH E6) Blind review
Sources: en.wikipedia.org
== External links == Sharma, Vasundhara; Rao, Lingamallu Jagan Mohan (January 2014). "An Overview on Chemical Composition, Bioactivity and Processing of Leaves of Cinnamomum tamala". Critical Reviews in Food Science and Nutrition. 54 (4): 433–448. doi:10.1080/10408398.2011.587615. PMID 24236996. S2CID 46178245. Pandey, A. K.; Mishra, A. K.; Mishra, A. (22 December 2012). "Antifungal and antioxidative potential of oil and extracts derived from leaves of Indian spice plant Cinnamomum tamala". Cellular and Molecular Biology. 58 (1): 142–147. PMID 23273204. Indian bay-leaf page from Gernot Katzer's Spice Pages
For services to Music. International list John Adams. Chair, British Retirement Home Association, Portugal. For services to the Community and Voluntary Organisations in Portugal. Joy Atkinson. Desk Officer, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Nicola Jane Barrett. Head, Corporate Services, British Embassy Moscow, Russia. For services to British Foreign Policy. Liza Barry. Deputy Director, Foreign, Commonwealth and Development Office. For services to National Security. Geoffrey James Booker. Founding Chairman and Field Director, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Geraldine Elizabeth Booker. Director of Development, The Quicken Trust and The GB Trust. For services to the community in Kabubbu, Uganda. Sian Bowsley. Head, Agrifood and Sanitary and Phytosanitary (SPS), Windsor Framework Taskforce, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Christopher Mark Broadbent. Team Leader, Foreign, Commonwealth and Development Office. For services to National Security. Keith John Buckley. Chairman, British Chamber of Commerce, Macao; Chairman, The Lighthouse Club (Macao Branch) charity. For services to the Local Community and British Interests in Macao. Scott Arthur Burgess. Acting Overseas Security Manager, British Embassy Tehran, Iran. For services to the British Embassy Tehran. Adina Diana Esther Munroe-Charlow. Chairperson, Royal British Legion, Bahamas Branch. For services to Veterans in The Bahamas. Gillian Clasby.
== ADLM Annual Scientific Meeting == ADLM holds several scientific conferences each year, the largest of which is the ADLM Annual Scientific Meeting & Clinical Lab Expo. First held in 1949, this educational meeting and technology exposition is an event in the field of laboratory medicine, attracting an average of 20,000 participants.
Sources: en.wikipedia.org
==== Monoclonal antibodies ==== Monoclonal antibodies have long been considered for OI, but as of 2021, such therapy has not been approved for OI, neither in the European Union nor in the United States. Thus, it is unclear whether they are safe or effective. Among the monoclonal antibodies that have been studied are romosozumab (targets sclerostin, by Amgen), fresolimumab (TGF-β, Sanofi), blosozumab (sclerostin, Lilly), and setrusumab (sclerostin, begun by Novartis). Setrusumab, formerly known as BPS-804, is a monoclonal antibody that targets sclerostin, and has been studied in OI specifically more than any of the others. In the body, sclerostin binds to the LRP5 and LRP6 receptors, resulting in inhibition of the Wnt signaling pathway. This decreases bone formation, and is not a problem when a person has healthy bones. It is thought, though, that decreasing the concentration of sclerostin in the body may lead to the formation of more bone, and that is the premise as to why monoclonal antibodies that reduce the concentrations of naturally occurring sclerostin may help strengthen OI bone. While setrusumab was first developed at the pharmaceutical company Novartis, Novartis sold its rights to patent the drug to Mereo Biopharma in 2015, who has continued its development in conjunction with Ultragenyx. In 2019, Mereo announced that it had concluded collecting data for its phase II-B trial of setrusumab; the study was completed on 12 November 2020.
== References == Courtnall, Roy; Johnson, Chris (1999). The Art of Violin Making. London: Robert Hale. ISBN 0-7090-5876-4. Patrick Spielman. Gluing and Clamping: A Woodworker's Handbook. Sterling Publishing, 1986. ISBN 0-8069-6274-7 Weisshaar, Hans; Shipman, Margaret (1988). Violin Restoration. Los Angeles: Weisshaar~Shipman. ISBN 0-9621861-0-4.
== Early life == James Rowley French was born on September 23, 1928, in Pasadena, California, to Mabelle (née Rowley) and James Forrest French. French got his first job in radio as a teenager, on the Pasadena AM station KXLA. French enlisted in the U.S. Army in 1945 and was stationed in allied-occupied Japan, where he worked for the Armed Forces Radio. He attended the Pasadena City College following his discharge.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.